secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2023-08-15T23:59:59+00:00
Accession:  0001326110-23-000102
Event type: litigation
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bankruptcy court approves Sorrento settlement; two scenarios could resolve ImmunityBio litigation
--------------------------------------------------------------------------------

- Bankruptcy court approved settlement on Aug 14, 2023 between ImmunityBio and Sorrento (Case No. 23-90085).
- Scenario A: If Sorrento raises funds by Aug 31, it pays judgments to NantCell and NANTibody and can proceed with litigation.
- Scenario B: If not, judgments released, Sorrento relinquishes interests in NANTibody and forfeits antibody license rights.
- As of June 30, 2023, ImmunityBio had recorded no receivables on the judgments; outcome remains uncertain.
- Settlement includes release of derivative litigation in Los Angeles Superior Court; now binding on parties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611023000102/0001326110-23-000102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611023000102/ibrx-20230814.htm
  HTML page:      https://secwatch.observer/filing/0001326110-23-000102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer